PDF(Pubmed)
Abstract：
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course and choosing the best treatment strategy for the patient remains challenging. A multitude of clinical trials is ongoing, opening multiple opportunities for enrollment. In this brief review we discuss the current approach to the management of IgAN and highlight the ongoing clinical trials.
摘要：
IgA肾病（IgAN）是全球最常见的原发性肾小球肾炎。最近,在对IgAN病理生理学和治疗方案的理解方面取得了多项进展.尽管出现了新的治疗选择，病程的个体风险分层和为患者选择最佳治疗策略仍然具有挑战性.大量的临床试验正在进行中，开放多个入学机会。在这篇简短的综述中，我们讨论了目前IgAN的管理方法，并强调了正在进行的临床试验。
